← Back to Patent Explorer
US5756673A Expired / Lapsed US ⏱️ 0.0 years remaining

Regulation of smooth muscle cell proliferation

Assignee: Boston University
•
Filing: 1995-06-06
•
Granted: 1998-05-26
•
Expires: 2015-06-06
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This invention relates to agents that regulate the proliferation of cells such as smooth muscle cells. Proliferation of smooth muscle cells may be increased or decreased by affecting the activity or concentration of a transcription factor. The factor comprises two domains of about 50 kD and about 70 kD which together have an approximate molecular weight of 120 kD and specifically binds to the nucleic acid sequence 5'-GGGTTTTCCCC-3' (SEQ ID NO 2). This factor represents a novel member of the family of rel-related factors. This invention also relates to methods for the treatment and prevention of diseases and disorders associated with proliferation of smooth muscle cells such as arteriosclerosis, fibrosis and wound healing, which involve regulation of the smooth muscle cell transcription factor. The invention further relates to purified transcription factor, to pharmaceutical compositions containing transcription factor or inhibitors or inducers of the transcription factor, to nucleic acid sequences which code for the subunits of the factor, and to recombinant cells transformed with these sequences. Novel rel-related factors can also be used to regulate gene expression and the proliferation of organisms such as cells and viruses which may contain rel-related binding elements.

Inventors

  • 👤 Gail E. Sonenshein
  • 👤 Roger Lawrence
  • 👤 Robert E. Bellas

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 12:34
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4702; A; A61; A61K; A61K38/00

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 53 words
A purified transcription factor wherein said factor is comprised of two subunits of 50 and 70 kD that have a combined molecular weight of 120 kD wherein neither subunit is c-rel, rel B, or p65, and said factor specifically binds to a double-stranded nucleic acid containing the sequence 5'-GGGTTTTCCCC-3' (SEQ ID NO 2).
Claim 2
Dependent Claim 53 words
A purified transcription factor wherein said factor is comprised of two subunits of 50 and 70 kD that have a combined molecular weight of 120 kD wherein neither subunit is c-rel, rel B, or p65, and said factor specifically binds to a double-stranded nucleic acid containing the sequence 5'-GGGTTTTCCCC-3' (SEQ ID NO 2).
Claim 3
Dependent Claim 15 words
The factor of claim 1 wherein said factor regulates the proliferation of smooth muscle cells.
Claim 4
Dependent Claim 15 words
The factor of claim 1 wherein said factor is constitutively expressed in smooth muscle cells.
Claim 5
Dependent Claim 14 words
The factor of claim 1 wherein said factor binds only to double-stranded nucleic acids.
Claim 6
Dependent Claim 8 words
A composition comprising the factor of claim 1.
Claim 7
Dependent Claim 30 words
The composition of claim 5 further comprising a pharmaceutically acceptable carrier selected from the group consisting of water, oils, fatty acids, alcohols, salts, saccharides, polysaccharides, celluloses, starches and combinations thereof.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2001-05-25 2001-11-24 2002-05-26 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2005-05-25 2005-11-24 2006-05-26 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2009-05-25 2009-11-24 2010-05-26 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag